Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. PrimaPharm Inc.
WARNING LETTER
•PrimaPharm Inc.•May 14, 2008

PrimaPharm Inc. – FDA Warning Letter, May 14, 2008

Record Details

An FDA inspection of PrimaPharm Inc.'s drug manufacturing facility in San Diego, California, from May 1-14, 2008, revealed significant violations of current Good Manufacturing Practice (CGMP) regulations (21 CFR Part 211), causing their drug products to be adulterated under 21 U.S.C. § 351(a)(2)(B). The inspection also found the firm was manufacturing and marketing unapproved new drugs, violating 21 U.S.C. § 355(a), and that these drugs were misbranded, violating 21 U.S.C. § 352(f)(1).

Key CGMP deviations included: 1. **Inadequate investigations:** Failure to thoroughly investigate unexplained discrepancies, such as media fill failures and out-of-specification results, and to assess the impact on other batches. 2. **Microbiological contamination prevention failures:** Lack of continuous environmental monitoring, inadequate facility design (e.g., direct entry into aseptic areas), and deficient media fill validation procedures. 3. **Environmental monitoring deficiencies:** Failure to sample critical surfaces, perform viable air sampling at the conclusion of product fills, and establish appropriate action limits for personnel monitoring. 4. **Inadequate test method validation:** Lack of defined methods for determining operator qualification for visual inspection and undocumented retraining frequency. 5. **Insufficient cleaning and disinfection

Company
PrimaPharm Inc.
Inspection date
May 14, 2008
Product type
Drugs
Office
Los Angeles District Office
People
  • Alonza E. Cruse (Director)
  • Jeff Farrar
View Company Profile

ID · f000ff8a-86e3-44c5-8e58-a9022137ff5e

Violation Codes10
21 U.S.C. 321(g)21 CFR 21121.U.S.C. 355(a)21 U.S.C. 352(f)(1)21 CFR 201.11521 CFR 33021 CFR 33121 CFR 35821 CFR 211.19221 CFR 211.113(b)

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore PrimaPharm Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.